China’s Outbound

Pharma Play

Global pharmaceutical deal value soared to a record USD 275.1 billion in 2025, with Chinese companies creating nearly half of that value. 

As outbound licensing activity accelerates, global pharma companies are competing fiercely for high-potential assets while facing mounting pressure to execute increasingly complex cross-border deals faster, manage diligence at scale and modernize outdated workflows.

Read the report to learn:

• How China emerged as a driving force in global pharma dealmaking
• Why big-ticket licensing deals are surging in the region
• Which therapies and modalities are attracting the highest bids
• How diligence-ready targets are gaining a competitive edge
• Technology’s role in executing cross-border deals